Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression: Correlation with androgen independence

Rajal B. Shah, Debashis Ghosh, James T. Elder

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-naïve group. CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.

Original languageEnglish (US)
Pages (from-to)1437-1444
Number of pages8
JournalProstate
Volume66
Issue number13
DOIs
StatePublished - Sep 13 2006
Externally publishedYes

Keywords

  • Androgen independence
  • Epidermal growth factor receptor
  • Prostate cancer
  • Tumor progression

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression: Correlation with androgen independence'. Together they form a unique fingerprint.

  • Cite this